Therapeutic angiogenesis in patients with systemic sclerosis by autologous transplantation of bone-marrow-derived cells
Yoshiaki Ishigatsubo1 , Atsushi Ihata1 , Hiroshi Kobayashi1 , Maasa Hama1 , Yohei Kirino1 , Atsuhisa Ueda1 , Mitsuhiro Takeno1 , Akira Shirai2 , Shigeru Ohno3
5 November 2009
15 January 2010
19 February 2010
PDF (member's only)
We examined the efficacy and safety of autologous transplantation of bone-marrow-derived cells in patients with intractable ulcers caused by systemic sclerosis. Eight patients with ulcers resistant to treatment were enrolled. Bone marrow cells were gathered from the bilateral iliac crests with multiple repositioning bone marrow needles, and bone-marrow-derived mononuclear cells were isolated and injected into skeletal muscles of the ischemic limb. Visual analog scale (VAS), Sclerosis Health Assessment Questionnaire (SHAQ), modified Rodnan total skin score (mTSS), and the size and depth of the ulcer were examined. Thermography, capillaroscopy, intra-arterial digital subtraction angiography (IA-DSA), and laser Doppler flowmetry were also examined before and after transplantation. In all patients, reduction of ulcer size and improvement of VAS were observed after treatment. Elevation of surface temperature, increase of blood flow volume, and new capillaries of the nail bed were also found after our treatment. There were no major adverse effects of this treatment. Autologous transplantation of bone-marrow-derived cells was shown to be a novel and useful approach to intractable ulcers in systemic sclerosis.
Systemic sclerosis - Angiogenesis - Bone-marrow-derived cells - Autologous transplantation - Intractable ulcer